查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046313

誘導多功能細胞市場－全球產業規模、佔有率、趨勢、機會、預測：依細胞誘導類型、應用、最終用戶、區域和競爭格局分類，2021-2031年

Induced Pluripotent Stem Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Derived Cell Type, By Application, By End user By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球誘導多功能細胞 (iPSC) 市場預計將從 2025 年的 17.2 億美元大幅成長至 2031 年的 30.2 億美元，複合年成長率高達 9.84%。

誘導性多功能幹細胞（iPS細胞）由成體細胞經基因重編程後生成，並恢復到類似胚胎的狀態。這賦予了它們分化成人體內任何細胞類型的能力。這種多功能性使iPS細胞成為再生醫學、疾病模式和藥物研發領域不可或缺的工具。推動該市場發展的主要動力是癌症和神經退化性疾病等慢性疾病發生率的不斷上升，這些疾病亟需創新治療方法的開發。 iPS細胞的一大優勢在於它們避免了與胚胎幹細胞相關的倫理問題，從而促進了其在全球醫療機構的臨床研究和個人化醫療中的應用。儘管發展前景廣闊，但該市場仍面臨著許多挑戰，特別是生產規模化以及為防止致瘤性而必須採取的嚴格品管措施所帶來的高昂成本。確保iPS細胞在臨床應用中的安全性和一致性仍然是一個複雜的技術難題，開發者必須克服這個難題才能實現廣泛的商業性可行性。儘管如此，該領域仍持續獲得大量資金支持，並取得了持續進展。例如，再生醫學聯盟在 2025 年 1 月報告稱，細胞和基因治療領域已吸引了高達 152 億美元的投資，比前一年成長了 30%，這證實了支持這些技術進步的資金流入仍在繼續。

市場概覽
預測期 2027-2031
市場規模：2025年 17.2億美元
市場規模：2031年 30.2億美元
複合年成長率：2026-2031年 9.84%
成長最快的細分市場 藥物研發
最大的市場 北美洲

市場促進因素

隨著基於誘導多能幹細胞（iPSC）的再生醫學產品線不斷擴展，以及實驗性治療方法穩步推進至後期臨床試驗階段，市場格局正在發生根本性重塑。研發人員正在克服與細胞活力和移植率相關的傳統挑戰，累積商業化所需的關鍵臨床證據。在複雜疾病的治療領域，這項進展尤其顯著，因為在這些疾病中，替換受損或流失的組織是唯一有效的治療方法。例如，2025年10月，BlueRock Therapeutics公司宣布了其iPS細胞衍生在臨床實驗藥物bemdaneprocel的36個月積極療效。這些結果表明，該藥物在帕金森氏症患者中具有良好的安全性，並能維持三年以上的細胞活力。這些成果顯著降低了相關人員和監管機構的風險認知，並加快了iPS細胞產品獲得市場核准的進程。同時，慢性病和神經退化性疾病的日益普遍也迫使業界將重點放在根治性細胞療法而非症狀治療上。在諸如1型糖尿病等高負擔疾病中，對功能性替代細胞的迫切需求正推動著產品的快速研發和監管申報的準備工作。例如，2025年4月，青少年糖尿病治療聯盟（幼年型糖尿病 Cure Alliance）報告稱，Vertex Pharmaceuticals計劃於2026年向全球監管機構提交其iPS細胞衍生的胰島細胞療法zimislecel。這種致力於解決多種慢性疾病的統一關注，是由不斷擴展的全球臨床研究趨勢所驅動的。根據再生醫學聯盟（Alliance for Regenerative Medicine）於2025年1月發布的《產業趨勢簡報》，該領域正在進行的臨床試驗數量已接近2000項，凸顯了旨在解決這些緊迫的全球健康挑戰的廣泛研發工作。

市場挑戰

阻礙市場擴張的主要障礙在於生產規模化的巨大挑戰以及嚴格的品管所帶來的高昂成本。與傳統的小分子藥物不同，誘導多能幹細胞（iPS細胞）涉及複雜的生物過程，這使得大規模生產批次的標準化本身就十分困難。研發人員必須實施全面的安全規程，以確保表現型一致性並消除潛在的致癌風險，這顯著增加了單位生產成本。這些經濟和技術上的雙重負擔直接限制了這些先進治療方法的量產能力，阻礙了從臨床試驗成功到廣泛商業化的過渡。因此，快速的研發進展與當前的生產能力之間的差距正在擴大，為新參與企業造成了巨大的瓶頸。根據國際細胞與基因治療學會（ISCT）預測，到2025年，全球在研治療方法將達到3063種。如此龐大的在研治療方法數量給現有基礎設施帶來了巨大壓力。高昂的生產成本和有限的加工能力阻礙了這些創新產品有效率地推向市場。如果無法可靠地大規模生產 iPS 細胞，該領域將難以有效滿足日益成長的新治療方法需求。

市場趨勢

人工智慧 (AI) 與製程最佳化和藥物研發的融合，透過有效解決幹細胞生產中固有的生物異質性問題，正在顯著改變誘導多能幹細胞 (iPSC) 市場。開發人員正擴大採用機器學習演算法來分析複雜的細胞行為並實現分化方案的自動化，從而顯著降低批次間的差異，而這種差異往往會阻礙臨床應用。這種技術協同作用使得在工業規模上精確控制細胞成為可能，確保了獲得監管核准所必需的表現型均一性。例如，bit.bio 於 2025 年 11 月宣布啟動其「ioHepatocytes」早期准入計劃，該計劃將引入一種標準化的 iPSC 衍生肝臟模型，該模型旨在利用其精準的細胞再程式化平台，克服傳統藥物篩檢方法中普遍存在的異質性問題。同時，iPSC 衍生的 3D 類器官和晶片器官技術的出現，透過提供生理學上有效的替代傳統動物試驗的方法，正在革新臨床前評估。與單層培養相比，這些複雜的3D微組織能夠更精確地模擬人體器官的結構和功能，顯著提高毒理學和療效篩檢的預測準確性。這一趨勢主要得益於聯邦政府致力於建立標準化的非動物試驗框架，以加速治療方法的研發。正如FierceBiotech在2025年9月報道的那樣，美國國立衛生研究院（NIH）撥款8700萬美元，用於建立一個「標準化類器官建模中心」。該中心是一個專門機構，旨在檢驗和推廣這些基於誘導多能幹細胞（iPSC）的工具，以便監管機構和行業廣泛採用。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：誘導多功能細胞的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 細胞來源類型（肝細胞、纖維母細胞、角質細胞、神經細胞等）
    • 依應用領域（藥物發現、再生醫學、毒性測試、組織工程、細胞治療、疾病模型）
    • 按最終用戶（研究機構、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美誘導多功能細胞市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲誘導多功能細胞市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區誘導多功能細胞市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲誘導多功能細胞市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲誘導多功能細胞市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球誘導多功能細胞市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Axol Bioscience Ltd.
  • Cynata Therapeutics Limited
  • Evotec SE
  • Fate Therapeutics, Inc.
  • FUJIFILM Cellular Dynamics, Inc.
  • Ncardia Services BV.
  • Reprocell USA, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takara Bio, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16737

The Global Induced Pluripotent Stem Cells (iPSC) Market is projected to expand significantly, growing from USD 1.72 Billion in 2025 to USD 3.02 Billion by 2031, demonstrating a robust Compound Annual Growth Rate (CAGR) of 9.84%. Induced pluripotent stem cells are derived from adult somatic cells that undergo genetic reprogramming, reverting them to an embryonic-like state where they gain the capacity to differentiate into any cell type in the human body. This versatile capability positions iPSCs as an essential asset in regenerative medicine, disease modeling, and drug discovery. The market's primary impetus stems from the escalating incidence of chronic diseases, such as cancer and neurodegenerative conditions, which demand innovative therapeutic solutions. A key advantage of iPSCs is their ability to bypass the ethical concerns associated with embryonic stem cells, thereby encouraging wider adoption in clinical research and personalized medicine initiatives across the global healthcare landscape. Despite this promising growth trajectory, the market faces notable challenges, particularly regarding manufacturing scalability and the substantial costs linked to stringent quality control measures essential for preventing tumorigenicity. Ensuring the safety and consistency of iPSCs for clinical application remains a complex technical barrier that developers must overcome to achieve widespread commercial viability. Nevertheless, the sector continues to receive strong financial backing, indicating sustained progress. For instance, the Alliance for Regenerative Medicine reported in January 2025 that the cell and gene therapy sector attracted an impressive $15.2 billion in investment, marking a 30% increase from the prior year, which underscores the continuous capital flow supporting these technological advancements.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.72 Billion
Market Size 2031USD 3.02 Billion
CAGR 2026-20319.84%
Fastest Growing SegmentDrug Development
Largest MarketNorth America

Market Driver

The market is fundamentally being reshaped by the expanding pipeline of iPSC-based regenerative therapies, as experimental treatments increasingly advance through late-stage clinical validation. Developers are successfully addressing previous obstacles related to cell survival and engraftment, thereby accumulating crucial clinical evidence necessary for commercialization. This progress is particularly evident in treating complex conditions where the replacement of damaged or lost tissue offers the only viable cure. As an illustration, BlueRock Therapeutics announced in October 2025 positive 36-month results for its investigational iPSC-derived therapy, bemdaneprocel, which showed a favorable safety profile and sustained cell survival in Parkinson's disease patients over three years. Such achievements significantly mitigate perceived risks for both stakeholders and regulators, thus accelerating the path of iPSC products toward market approval. Simultaneously, the rising prevalence of chronic and neurodegenerative disorders is compelling the industry to prioritize curative cell therapies over symptomatic management strategies. The urgent requirement for functional replacement cells in conditions with high disease burden, such as type 1 diabetes, is catalyzing rapid advancements in product development and readiness for regulatory submissions. For example, the Juvenile Diabetes Cure Alliance reported in April 2025 that Vertex Pharmaceuticals is on track to submit its global regulatory filing for zimislecel, an iPSC-derived islet cell therapy, in 2026. This concerted focus on tackling widespread chronic diseases is bolstered by a broadening clinical research landscape globally. The Alliance for Regenerative Medicine's January 2025 'State of the Industry Briefing' revealed that the number of active clinical trials in the sector has nearly reached 2,000, emphasizing the extensive scope of development activities aimed at addressing these pressing global health challenges.

Market Challenge

The primary obstacle hindering market expansion is the substantial challenge of manufacturing scalability and the prohibitive costs associated with stringent quality control. Unlike conventional small-molecule pharmaceuticals, induced pluripotent stem cells involve intricate, living biological processes that are inherently difficult to standardize across large production batches. Developers must implement exhaustive safety protocols to ensure phenotypic consistency and eliminate potential tumorigenic risks, which significantly inflates the production expenses per unit. This combined financial and technical burden directly limits the capacity to mass-produce these advanced therapies, thereby impeding their transition from successful clinical trials to widespread commercial availability. Consequently, a growing disparity exists between the rapid pace of research advancements and the current manufacturing capacity, creating a significant bottleneck for new market entrants. According to the International Society for Cell & Gene Therapy, the global pipeline expanded to include 3,063 therapies under development in 2025. This substantial volume of developing treatments exerts immense pressure on existing infrastructure, where high production costs and constrained throughput capabilities prevent these innovative products from efficiently reaching the market. Without the ability to reliably manufacture iPSCs at a commercial scale, the sector struggles to effectively meet the escalating demand for novel therapeutic interventions.

Market Trends

The integration of Artificial Intelligence (AI) for process optimization and drug discovery is profoundly transforming the iPSC market by effectively addressing the biological heterogeneity intrinsic to stem cell production. Developers are increasingly deploying machine learning algorithms to interpret complex cellular behaviors and automate differentiation protocols, which significantly reduces the batch-to-batch variability that frequently impedes clinical translation. This technological synergy enables the precision engineering of cells on an industrial scale, ensuring the phenotypic uniformity crucial for regulatory approval. For instance, bit.bio announced in November 2025 the launch of its Early Access program for ioHepatocytes, leveraging its precision cellular reprogramming platform to introduce standardized iPSC-derived liver models specifically designed to overcome the inconsistency issues prevalent in traditional drug screening methods. Concurrently, the emergence of iPSC-derived 3D organoids and organ-on-chip technologies is revolutionizing preclinical assessment by providing physiologically relevant alternatives to conventional animal testing. These complex, three-dimensional micro-tissues more accurately replicate human organ architecture and function compared to monolayer cultures, leading to a substantial improvement in the predictive validity of toxicology and efficacy screening. This trend is significantly supported by federal initiatives focused on establishing standardized, non-animal testing frameworks to accelerate therapeutic development. As reported by FierceBiotech in September 2025, the National Institutes of Health (NIH) allocated $87 million in contracts to establish the Standardized Organoid Modeling Center, a dedicated resource aimed at validating and scaling these iPSC-based tools for widespread adoption in regulatory and industrial applications.

Key Market Players

  • Axol Bioscience Ltd.
  • Cynata Therapeutics Limited
  • Evotec SE
  • Fate Therapeutics, Inc.
  • FUJIFILM Cellular Dynamics, Inc.
  • Ncardia Services B.V..
  • Reprocell USA, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takara Bio, Inc.

Report Scope

In this report, the Global Induced Pluripotent Stem Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Induced Pluripotent Stem Cells Market, By Derived Cell Type

  • Hepatocytes
  • Fibroblasts
  • Keratinocytes
  • Neurons
  • Others

Induced Pluripotent Stem Cells Market, By Application

  • Drug Development
  • Regenerative Medicine
  • Toxicity Testing
  • Tissue Engineering
  • Cell Therapy
  • Disease Modeling

Induced Pluripotent Stem Cells Market, By End user

  • Research Institutions
  • Other

Induced Pluripotent Stem Cells Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Induced Pluripotent Stem Cells Market.

Available Customizations:

Global Induced Pluripotent Stem Cells Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Induced Pluripotent Stem Cells Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Derived Cell Type (Hepatocytes, Fibroblasts, Keratinocytes, Neurons, Others)
    • 5.2.2. By Application (Drug Development, Regenerative Medicine, Toxicity Testing, Tissue Engineering, Cell Therapy, Disease Modeling)
    • 5.2.3. By End user (Research Institutions, Other)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Induced Pluripotent Stem Cells Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Derived Cell Type
    • 6.2.2. By Application
    • 6.2.3. By End user
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Induced Pluripotent Stem Cells Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Derived Cell Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End user
    • 6.3.2. Canada Induced Pluripotent Stem Cells Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Derived Cell Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End user
    • 6.3.3. Mexico Induced Pluripotent Stem Cells Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Derived Cell Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End user

7. Europe Induced Pluripotent Stem Cells Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Derived Cell Type
    • 7.2.2. By Application
    • 7.2.3. By End user
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Induced Pluripotent Stem Cells Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Derived Cell Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End user
    • 7.3.2. France Induced Pluripotent Stem Cells Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Derived Cell Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End user
    • 7.3.3. United Kingdom Induced Pluripotent Stem Cells Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Derived Cell Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End user
    • 7.3.4. Italy Induced Pluripotent Stem Cells Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Derived Cell Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End user
    • 7.3.5. Spain Induced Pluripotent Stem Cells Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Derived Cell Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End user

8. Asia Pacific Induced Pluripotent Stem Cells Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Derived Cell Type
    • 8.2.2. By Application
    • 8.2.3. By End user
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Induced Pluripotent Stem Cells Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Derived Cell Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End user
    • 8.3.2. India Induced Pluripotent Stem Cells Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Derived Cell Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End user
    • 8.3.3. Japan Induced Pluripotent Stem Cells Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Derived Cell Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End user
    • 8.3.4. South Korea Induced Pluripotent Stem Cells Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Derived Cell Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End user
    • 8.3.5. Australia Induced Pluripotent Stem Cells Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Derived Cell Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End user

9. Middle East & Africa Induced Pluripotent Stem Cells Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Derived Cell Type
    • 9.2.2. By Application
    • 9.2.3. By End user
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Induced Pluripotent Stem Cells Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Derived Cell Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End user
    • 9.3.2. UAE Induced Pluripotent Stem Cells Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Derived Cell Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End user
    • 9.3.3. South Africa Induced Pluripotent Stem Cells Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Derived Cell Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End user

10. South America Induced Pluripotent Stem Cells Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Derived Cell Type
    • 10.2.2. By Application
    • 10.2.3. By End user
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Induced Pluripotent Stem Cells Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Derived Cell Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End user
    • 10.3.2. Colombia Induced Pluripotent Stem Cells Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Derived Cell Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End user
    • 10.3.3. Argentina Induced Pluripotent Stem Cells Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Derived Cell Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Induced Pluripotent Stem Cells Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Axol Bioscience Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Cynata Therapeutics Limited
  • 15.3. Evotec SE
  • 15.4. Fate Therapeutics, Inc.
  • 15.5. FUJIFILM Cellular Dynamics, Inc.
  • 15.6. Ncardia Services B.V..
  • 15.7. Reprocell USA, Inc.
  • 15.8. Sumitomo Dainippon Pharma Co., Ltd.
  • 15.9. Takara Bio, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer